Bronchiectasis insanity

Doing the same thing over and over again and expecting different results?

Mark Metersky (Lead / Corresponding author), James Chalmers

Research output: Contribution to journalReview article

1 Citation (Scopus)
40 Downloads (Pure)

Abstract

Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.

Original languageEnglish
Article number293
Pages (from-to)1-7
Number of pages7
JournalF1000Research
Volume8
DOIs
Publication statusPublished - 15 Mar 2019

Fingerprint

Bronchiectasis
Medicine
United States Food and Drug Administration
Therapeutics
Quality of Life
Clinical Trials
Morbidity

Keywords

  • Bronchiectasis
  • Clinical trial
  • Treatment

Cite this

@article{e4c8bc91486246d38ae3c5900ed08911,
title = "Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?",
abstract = "Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.",
keywords = "Bronchiectasis, Clinical trial, Treatment",
author = "Mark Metersky and James Chalmers",
year = "2019",
month = "3",
day = "15",
doi = "10.12688/f1000research.17295.1",
language = "English",
volume = "8",
pages = "1--7",
journal = "F1000 Research",
issn = "2046-1402",
publisher = "F1000Research",

}

Bronchiectasis insanity : Doing the same thing over and over again and expecting different results? / Metersky, Mark (Lead / Corresponding author); Chalmers, James.

In: F1000Research, Vol. 8, 293, 15.03.2019, p. 1-7.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bronchiectasis insanity

T2 - Doing the same thing over and over again and expecting different results?

AU - Metersky, Mark

AU - Chalmers, James

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.

AB - Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.

KW - Bronchiectasis

KW - Clinical trial

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85063713712&partnerID=8YFLogxK

U2 - 10.12688/f1000research.17295.1

DO - 10.12688/f1000research.17295.1

M3 - Review article

VL - 8

SP - 1

EP - 7

JO - F1000 Research

JF - F1000 Research

SN - 2046-1402

M1 - 293

ER -